Drugs Used in the Treatment of Gastrointestinal Diseases.

Drugs used in Peptic Ulcer Diseases.

Drugs Stimulating Gastrointestinal Motility.

Laxatives.
Antidiarrheal Agents.

Drugs used in Irritable Bowel Syndrome.

Antiemetic Agents.

Drugs used in Inflammatory Bowel Disease.

Pancreatic Enzyme Supplements.
Physiology of gastric Secretion

Stimulation of acid secretion involves translocation of H+/K+-ATPases to the apical membrane of parietal cell.

When the cell is resting proton pumps are inside the cell. Parietal cells secrete 2 liters of acid/ day.

Optimal pH (between 1.8-3.5) for the function of the digestive enzyme pepsin.

The H+/K+-ATPase (or proton pump) uses the energy derived from ATP hydrolysis to pump hydrogen ions into the lumen in exchange for potassium ions.

Chloride and hydrogen ions are secreted separately from the cytoplasm of parietal cells and mixed in the canaliculi.
Stimulants of acid secretion:

1- Ach from enteric neurons.
2- Histamine from ECL (enterochromaffin-like) cells.
3- Gastrin released by G cells.

Gastrin releasing peptide (GRP)
Somatostatin in D cells inhibits acid secretion. When the pH of the stomach gets too low, somatostatin secretion is stimulated. It inhibits acid secretion by:
1-direct effects on parietal cells.
2- inhibiting release of histamine & gastrin.

There are three phases in the secretion of gastric acid.
Cephalic Phase

sight, smell, taste or thought of food, activate enteric neurons via parasympathetic preganglionic neurons (vagus).

In humans, the major effect of gastrin upon acid secretion is mediated indirectly through the release of histamine from ECL cells rather than through direct parietal cell stimulation.
Gastric Phase

Food stretch the walls of the stomach, activating a neural reflex to stimulate acid secretion (purple).

Peptides and amino acids in food stimulate G cells to release gastrin (blue).

Food also acts as a buffer, raising the pH and thus removing the stimulus for somatostatin secretion (light blue-green).
**Intestinal Phase**

**Stimulus** - digested peptides, peptides in duodenum, distention, G cells (gastrin), distention --> Intestinal endocrine cells release entero-oxyntin hormone.

Gastric pH < 3 ---> gastric D cells release somatostatin

Once chyme enters the duodenum, it activates negative feedback mechanisms to reduce acid secretion.

**Enterogastrones**

hormones that inhibit acid secretion.

**CCK**: Cholecystokinin a *peptide hormone* of the GIS responsible for stimulating the *digestion* of *fat* and *protein*.

**GLP-1**: Glucagon-like peptide-1.

**GIP**: Gastric inhibitory polypeptide
Peptic ulcer
A defect in the lining of the stomach or the duodenum.

Causes of Peptic Ulcer:
*Helicobacter pylori* (most common). Drugs such as aspirin & other NSAIDs

Other factors:
Smoking, Stress, alcohol.

Gastrinomas
Zollinger Ellison syndrome
a rare gastrin-secreting tumors.
Symptoms:
burning pain in stomach between meals or at night, bloating, heartburn, nausea or vomiting.
In severe cases, symptoms include:
Dark or black stool (due to bleeding)
Vomiting blood (looks like coffee-grounds)
Weight loss & severe pain in the mid to upper abdomen.

Complications of peptic ulcer
Gastrointestinal bleeding.
(Sudden large bleeding can be life threatening).
Cancer (Helicobacter pylori as the etiological factor making it 3-6 times likely to develop stomach cancer)
Perforation (hole in the wall)
Penetration.
Treatment options

Reduce acid secretion or Neutralize acid in the lumen

Protect the mucosa from acid destruction

Antibiotics to eradicate *Helicobacter pylori*. If this is successful then the ulcer should begin to heal on its own.
Neutralization of acid (Antacids)
Nonprescription remedies for treatment of heartburn & dyspepsia.
Given 1 hour after a meal effectively neutralizes gastric acid for up to 2 hours.

\[ \text{AL(OH)}_3 + \text{HCl} \rightarrow \text{ALCl}_3 + \text{H}_2\text{O} \]
\[ 2\text{HCl} + \text{Mg(OH)}_2 \rightarrow \text{MgCl}_2 + 2\text{H}_2\text{O} \]

Aluminum antacids cause constipation, interfere with absorption of many drugs.
Magnesium antacids have laxative action; diarrhea. Ionic magnesium stimulates gastric release (acid rebound)
Magnesium trisilicate slow-acting antacid
Combination of Magnesium & aluminum antacids are most commonly used (No diarrhea or constipation).
Calcium carbonate associated with "acid rebound" with excessive, chronic use, it may cause: milk-alkali syndrome with elevation of: serum calcium, phosphate, urea nitrogen, creatinin, bicarbonate levels

$$2\text{HCl} + \text{CaCO}_3 \rightarrow \text{CaCl}_2 + \text{CO}_2 + \text{H}_2\text{O}$$

Sodium bicarbonate should be avoided; aggravate CHF & counteracts diuretic therapy for hypertension, short duration of action, followed by acid rebound, highly absorbed, potentially causing metabolic alkalosis. CO2 results in gastric distention and belching.

$$\text{NaHCO}_3 + \text{HCl} \rightarrow \text{NaCl} + \text{H}_2\text{O} + \text{CO}_2$$
H2-Receptor Antagonists

Cimetidine, Ranitidine, Famotidine, Nizatidine.
Rapidly absorbed from intestine.

Cimetidine, ranitidine, famotidine have first-pass metabolism bioavailability 50%.

Nizatidine has little first-pass metabolism.

Duration of action: 6–10 hours, given twice daily.

Inhibit 90% of nocturnal acid (depends on histamine).
Modest impact on meal-stimulated acid secretion (which is stimulated by gastrin, Ach and histamine).

Inhibit 60% of day-time, meal stimulated acid.

Inhibit 60-70% of total 24-h acid secretion.
Clinical Uses

Gastroesophageal Reflux Disease (GERD)
Taken prophylactically before meals. In erosive esophagitis H2 antagonists healing is less than 50%; hence PPI are preferred.

Non Ulcer Dyspepsia.
Over-the-counter agents for treatment of intermittent dyspepsia not caused by peptic ulcer.

Prevention of Bleeding from Stress-Related Gastritis
IV H2 antagonists are preferable over IV PPI because of their proven efficacy and lower cost.

Peptic Ulcer Disease:
Replaced by PPI.
Healing rate more than 80-90% after 6-8 wks.
Not effective in the presence of *H. pylori*.
Not effective if NSAID is continued.
Adverse Effects:
Extremely safe drugs. Diarrhea, headache, fatigue, myalgias, and constipation (3% ).

Cimetidine may cause gynecomastia & impotence in men (antiandrogenic effects) and galactorrhea in women

Drug Interactions:
Cimetidine inhibits cytochrome P450 enzymes so can increase half life of many drugs.
Ranitidine binds 4-10 times less.
Nizatidine and famotidine binding is negligible
Proton Pump Inhibitors (PPIs)

Among the most widely prescribed drugs worldwide due to their outstanding efficacy and safety.

- Omeprazole (oral).
- Rabeprazole (oral).
- Lanzoprazole (oral and IV).
- Pantoprazole (oral and IV).
- Esmoprazole (oral and IV).

**Prodrugs**, released in the intestine (Destroyed by acid).

Immediate Release Suspension *(contains sodium bicarbonate to protect the drug from acid degradation)* results in rapid response.
Lipophilic weak bases, absorbed in small intestine and delivered to parietal cell through the blood. Drug is protonated and “trapped” in acidic canaliculi. Concentrated more than 1000-fold within the parietal cells.

Converted to the **active form** which covalently binds the H⁺/K⁺ ATPase enzyme and inactivates it.
**Rabeprazole** and **immediate release omeprazole** have faster onsets of action. Given one hour before meal, usually breakfast. Have short half lives but effect lasts for 24 hours. At least 18 hours are required for synthesis of new pump molecules.

**Inhibit both fasting & meal-stimulated secretion** (90-98% of 24-hour secretion). The full acid-inhibiting potential is reached in 3 to 4 days.
Clinical Uses of (PPIs):

**Gastroesophageal Reflux (GERD):**
The most effective agents in all forms of EGRD

**Nonulcer Dyspepsia:**
Modest activity. 10-20% more beneficial than a placebo

**Stress-Related Gastritis:**
Oral immediate-release omeprazole administered by nasogastric tube.
For patients without a nasoenteric tube, IV H₂-blockers are preferred because of their proven efficacy.

**Gastric acid hypersecretory states, including Zollinger-Ellison syndrome**
Usually high doses of omeprazole are used.
Peptic Ulcer Disease:
They heal more than 90% of cases within 4-6 weeks.

_H.Pylori - associated ulcers:_
PPI eradicate _H.pylori_ by direct antimicrobial activity and by lowering MIC of the antibiotics.

**Triple Therapy:**
PPI twice daily + Clarithromycin 500 mg twice daily + Amoxicillin 1 gm twice daily, OR, Metronidazole 500 mg twice daily.

_NSAID-associated ulcers:_
promote healing despite continued NSAID
Also used to prevent ulcer of NSAIDs

_Rebleeding peptic ulcer:_
Oral or IV.
High pH may enhance coagulation and platelet aggregation.
Adverse Effects of PPIs:
Well tolerated, AE relatively uncommon.
May cause headache, diarrhea, abdominal pain, nausea & dizziness
Reduction of cyanocobalamin absorption.
Increased risk of GI and pulmonary infection.
**Increased serum gastrin levels causes:**
Hyperplasia of ECL cells and Carcinoid tumors in rats but not in humans.
Chronic inflammation in gastric body.
Atrophic gastritis and intestinal metaplasia

**Drug Interactions:**
May affect absorption of drugs due to decreased gastric acidity like **digoxin** and **ketoconazole**.
1- Both mucus and epithelial cell-cell tight junctions restrict back diffusion of acid and pepsin.
2- Epithelial bicarbonate secretion
3- Blood flow carries bicarbonate
4- Injured epithelium are repaired by restitution
5- Mucosal prostaglandins stimulates mucus and bicarbonate secretion and mucosal blood flow.
Sucralfate
A salt of sucrose complexed to sulfated aluminum hydroxide.

In the stomach, it breaks down into sucrose sulfate (strongly negatively charged) and an aluminum salt.

The negatively charged sucrose sulfate binds to positively charged proteins in the base of ulcers or erosion, forming a physical barrier that restricts further caustic damage and stimulates mucosal prostaglandin and bicarbonate secretion. Acts for up to 6 hours. Less than 3% of intact drug and aluminum is absorbed from GIT.
Clinical Uses

1 g four times daily on an empty stomach (through a nasogastric tube) reduces the incidence of upper GI bleeding in critically ill patients hospitalized in the intensive care unit.

Prevention of stress-related bleeding because acid inhibitory therapies may increase the risk of nosocomial pneumonia (an infection of the lungs that occurs during a hospital stay).

Adverse Effects

not absorbed, so devoid of systemic adverse effects.

Constipation (2%) due to the aluminum salt.

Caution in renal insufficiency.

Drug Interactions

Sucralfate may bind to other medications, impairing their absorption.
Prostaglandin Analogs

Misoprostol
A methyl analog of PGE1. Half-life is less than 30 min administered 3-4 times daily.

1- Stimulates mucus & bicarbonate secretion.
2- Enhance mucosal blood flow.
3- Acts on parietal cells, reducing histamine-stimulated cAMP production and causing modest acid inhibition.
4- Stimulates intestinal electrolyte & fluid secretion,
5- Increase intestinal motility
6- Uterine contractions.

Not widely used for this purpose because of:

a. side effects.
b. need for multiple daily dosing.
c. PPI may be as effective and better tolerated.
d. Cyclooxygenase2-selective NSAIDs are an option for such patients.

Adverse Effects & Drug Interactions

Diarrhea and cramping abdominal pain (10–20%). It should not be used during pregnancy.

No significant drug interactions are reported.
Colloidal Bismuth Compounds:

Bismuth subsalicylate.
Bismuth subcitrate.

Bismuth is minimally absorbed from GIT (< 1%).
A mucosal protective agent, provides coat on the ulcer.
To some extent it can
Reduce the gastric HCL secretion.
Help in eradication of H. pylori.
Stimulates the PGE secretion.
Reduce pepsin secretion.
Decrease H+ ion back diffusion.

Bismuth subsalicylate reduces stool frequency and liquidity in acute infectious diarrhea, due to salicylate inhibition of intestinal prostaglandin and chloride secretion.
Has direct antimicrobial effects & binds enterotoxins, so useful in preventing & treating traveler's diarrhea. Widely used for the nonspecific treatment of dyspepsia and acute diarrhea.

Has direct antimicrobial activity against *H pylori* and used as second-line therapy for the eradication of *H pylori* infection (a PPI with bismuth subsalicylate, tetracycline and metronidazole for 10–14 days).

**Adverse Effects**
Causes blackening of the stool and the tongue. Prolonged usage may rarely lead to bismuth toxicity, resulting in encephalopathy.
Drugs Stimulating GI Motility

(Prokinetic agents)

Potential uses:

Increasing lower esophageal sphincter pressures, useful for GERD.

Improving gastric emptying, helpful for gastroparesis and postsurgical gastric emptying delay.

Stimulation of the small intestine useful for postoperative ileus.

Enhancing colonic transit, useful in the treatment of constipation.
1- Gut distention stimulates 5-HT release from EC cells.

2- Stimulation of 5-HT3 receptors on the extrinsic afferent nerves, stimulate nausea, vomiting, or abdominal pain.

3- 5-HT also stimulates 5-HT1P receptors of the intrinsic primary afferent nerves (IPANs) which activate the enteric neurons responsible for peristaltic and secretory reflex activity.

4- Stimulation of 5-HT4 receptors (5-HT4R) on presynaptic terminals of IPANs enhances release of ACh & calcitonin-gene-related peptide (CGRP), promoting reflex activity.
The enteric nervous system can independently regulate GI motility and secretion.

The myenteric interneurons control:

- peristaltic reflex, promoting release of excitatory mediators proximally and inhibitory mediators distally.
- **Motilin** may stimulate excitatory neurons or muscle cells directly.
- **Dopamine** acts as an inhibitory neurotransmitter in the GIT, decreasing the intensity of esophageal and gastric contractions.
Cholinomimetic Agents

Bethanechol
Stimulates muscarinic $M_3$ receptors on muscle cells and at myenteric plexus synapses. Was used for the treatment of GERD and gastroparesis.

Neostigmine
AchE inhibitor can enhance gastric, small intestine, and colonic emptying.
IV neostigmine used for the treatment of acute large bowel distention (acute colonic pseudo-obstruction).
Administration of 2 mg results in prompt colonic evacuation of flatus and feces.
Cholinergic effects include excessive salivation, nausea, vomiting, diarrhea, and bradycardia.
Dopamine D2-receptor antagonists. Metoclopramide & Domperidone
D2 Antagonists.
DA inhibits cholinergic smooth muscle stimulation. These agents:
- increase esophageal peristaltic amplitude.
- increase lower esophageal sphincter pressure.
- enhance gastric emptying.
- have no effect on small intestine or colonic motility.
Also block dopamine D2 receptors in the chemoreceptor trigger zone of the medulla (area postrema), resulting in potent antinausea and antiemetic action.
Clinical Uses

Gastroesophageal Reflux Disease
Not effective with erosive esophagitis.
Not superior to antisecretory agents.
Used mainly in combination with antisecretory agents in patients with refractory heartburn.

Impaired Gastric Emptying (Gastroparesis)
widely used in post surgical and diabetic gastroparesis.
Metoclopramide is used to promote advancement of nasoenteric feeding tubes from the stomach into the duodenum.

Nonulcer Dyspepsia

Prevention of Vomiting

Postpartum Lactation Stimulation
Domperidone is used to promote postpartum lactation
Adverse Effects:

Metclopromide crosses BBB so can cause: Restlessness, drowsiness, insomnia, anxiety, agitation, extrapyramidal symptoms (dystonia, akathisia, parkinsonian features) and tardive dyskinesia.

Domperidone does not cross the BBB, so does not cause CNS effects.

Both drugs can elevate serum prolactin levels causing galactorrhea, gynecomastia, impotence and menstrual disorders.
Laxatives

Intermittent constipation is best prevented with:
- a high-fiber diet.
- adequate fluid intake.
- responding to nature's call.
- regular exercise.

**Bulk-Forming Laxatives**

Indigestible, hydrophilic colloids that absorb water, forming a bulky, emollient gel that distends the colon and promotes peristalsis. Effective within 1-3 days.

Common preparations include natural plant products (psyllium, methylcellulose, bran) and synthetic fibers (polycarbophil). Bacterial digestion of plant fibers within the colon may lead to increased bloating and flatus.
Stool Surfactant Agents (Softeners)

Docusate
Detergents or surfactants that act as stool-wetting and stool-softening agents, allowing the mixing of water, lipids, and fecal matter.
Alters intestinal permeability and increases net water and electrolyte secretions in the intestine.
Orally: Softening of feces within 1-3 days
Rectally: effective within 5 to 20 minutes.
Used in symptomatic treatment of constipation & in painful anorectal conditions such as [hemorrhoids](#) and [anal fissures](#) for people avoiding straining during bowel movements.

Glycerin suppository.
It works by irritating the lining of the intestine and increasing the amount of fluid, making it easier for stools to pass.
Lubricant/Emollient
Site of Action: Colon.
Onset of Action: 6 - 8 hours.
Causing lubrication of the stool & make it slippery, so that it slides through the intestine more easily.
It is not absorbed and increase the bulk of the intestinal contents as it reduces the water absorption

**Liquid paraffin**
Used to prevent and treat fecal impaction. Aspiration can result in a severe lipid pneumonitis. Long-term use can impair absorption of fat-soluble vitamins. Can slip out of anal sphincter and causer embarrassment not recommended for regular use.
Osmotic Laxatives

Soluble but nonabsorbable compounds that result in increased stool liquidity due to an increase in fecal fluid.

Nonabsorbable Sugars or Salts

Magnesium hydroxide (milk of magnesia)
Not used for prolonged periods in renal insufficiency due to the risk of hypermagnesemia.

Large doses of magnesium citrate & sodium phosphate cause Purgation: rapid bowel evacuation within 1-3 h. This might cause volume depletion.
Lactulose
Disaccharide, not absorbed causing retention of water through osmosis leading to softer, easier to pass stool.
in the colon, it is fermented by the gut flora producing osmotic metabolites causing severe flatus and cramps.
Drug of choice in hepatic encephalopathy to trap NH$_3$.
Lactulose is converted into lactic acid, which decreases the luminal pH. So, NH$_3$ is trapped and prevented from absorption.
Stimulant Laxatives
Direct stimulation of the enteric nervous system and colonic electrolyte and fluid secretion.

**Anthraquinone Derivatives:**

**Aloe, senna, and cascara**
Occur naturally in plants. Poorly absorbed & after hydrolysis in the colon, produce a bowel movement in 6–12 h when given orally and within 2 h when given rectally. Chronic use leads to a brown pigmentation of the colon known as "melanosis coli." Not carcinogenic.
Bisacodyl
Tablet and suppository for treatment of acute and chronic constipation induces bowel movement within 6–10 h orally and 30–60 minutes rectally. Safe for acute and long-term use.

Phenolphthalein
Removed from the market owing to concerns about possible cardiac toxicity.
Opioid Receptor Antagonists

Do not cross the BBB.
Block peripheral (µ) mu – opioid receptors without central analgesic effects.

**Methylnaltrexone**
Used for opioid- induced constipation in patients with advanced illness not responding to other agents
Given by S.C. injection every 2 days.

**Alvimopan**
Short-term use for postoperative ileus in hospitalized patients.
Given orally within 5 hours before surgery and twice daily after surgery until bowel function has recovered, but for no more than 7 days, because of possible cardiovascular toxicity.
Antidiarrheal Agents

Should not be used in patients with **bloody diarrhea, high fever, or systemic toxicity** because of the risk of worsening the underlying condition.

Used to control chronic diarrhea caused by irritable bowel syndrome (IBS) or inflammatory bowel disease.
Opioid Agonists

Inhibit presynaptic cholinergic nerves in the submucosal and myenteric plexuses and lead to increased colonic transit time and fecal water absorption.

They also decrease mass colonic movements

CNS effects and potential for addiction limit the usefulness of most.

**Loperamide**

Does not cross BBB, so No analgesic or addiction potential.

**Diphenoxylate**

Not analgesic in standard doses. Higher doses have CNS effects. Can cause dependence.

Commercial preparations contain small amounts of **atropine** which contribute to the antidiarrheal action.
Bile Salt-Binding Resins

Cholestyramine
Colestipol
Colesevelam

Malabsorption of bile salts cause diarrhea. (Crohn's disease or after surgical resection). They bind bile salts and decrease diarrhea caused by excess fecal bile acids. Can cause bloating, flatulence, constipation and fecal impaction.

Cholestyramine and colestipol reduce absorption of drugs and fat, but Colesevelam does not.
Octreotide:
*Synthetic octapeptide with actions similar to somatostatin.*

**Somatostatin**

A 14 amino acid peptide released in the GIT and pancreas as well as from the hypothalamus:

1. Inhibits release of many hormones.
2. Reduces intestinal fluid and pancreatic secretions.
3. Slows GIT motility and gallbladder contraction.
5. Inhibits secretion of some *anterior pituitary* hormones.
Clinical Uses:

1. Inhibition of endocrine tumor effects:
   Carcinoid and VIPoma (neuroendocrine tumors that secrete vasoactive intestinal polypeptide (VIP)) can cause secretory diarrhea, flushing & wheezing.

2. Diarrhea due to vagotomy or dumping syndrome (ingested foods bypass the stomach too rapidly) or short bowel syndrome and AIDS.

3. To stimulate motility in small bowel bacterial overgrowth or intestinal pseudo-obstruction secondary to scleroderma (a disease affecting the skin and other organs that is one of the autoimmune rheumatic diseases).
4- It inhibits pancreatic secretion, so used in patients with pancreatic fistula (leakage of pancreatic secretions from damaged pancreatic ducts).

5- treatment of pituitary tumors (e.g., acromegaly)

6- Sometimes used in gastrointestinal bleeding.

**Adverse Effects:**

Impaired pancreatic secretion may cause **steatorrhea** which can lead to fat-soluble vitamin deficiency.

Nausea, abdominal pain, flatulence, and diarrhea.

Formation of sludge or **gallstones**, because of inhibition of gallbladder contractility and fat absorption.

Hyper or hypoglycemia due to hormonal imbalance.

Hypothyroidism.

Bradycardia.
Drugs Used in the Treatment of Irritable Bowel Syndrome

**IBS** is an idiopathic chronic, relapsing disorder characterized by:
Abdominal discomfort
pain, bloating, distention, or cramps with alterations in bowel habits
diarrhea, constipation, or both.

Pharmacologic therapies for IBS are directed at relieving abdominal pain and discomfort and improving bowel function.
**Antispasmodics (Anticholinergics)**

**Dicyclomine and Hyoscyamine.**
Block muscarinic receptors in the enteric plexus and on smooth muscle.

Their efficacy for relief of abdominal symptoms has never been convincingly demonstrated.

Low doses cause minimal autonomic effects.

Higher doses cause anticholinergic effects, including dry mouth, visual disturbances, urinary retention, and constipation.

For these reasons, antispasmodics are infrequently used.
Serotonin 5-HT3-Receptor Antagonists

Inhibition of afferent GIT 5-HT3 receptors reduce nausea, bloating, and pain.

Blockade of central 5-HT3 receptors also reduces the central response to visceral afferent stimulation.

5-HT3-receptor blockade on the terminals of enteric cholinergic neurons inhibits colonic motility, especially in the left colon, increasing total colonic transit time.
Alosetron
Potent & selective antagonist of the 5-HT3 receptor. Rapidly absorbed, half-life of 1.5 hours but has a much longer duration of effect.

Alosetron is restricted to women with severe diarrhea-predominant IBS not responding to conventional therapies.

Can cause ischemic colitis, severe constipation requiring hospitalization and surgery.

Its efficacy in men has not been established.
Serotonin 5-HT4-Receptor Agonists

Stimulation of 5-HT4 receptors on the presynaptic terminal of submucosal intrinsic primary afferent nerves enhances the release of their neurotransmitters, which promote the peristaltic reflex.

**Tegaserod**

was approved for the short-term treatment of women with IBS who had predominant constipation.

Removed from the market due to an increased number of cardiovascular deaths.

**Prucalopride**

High-affinity 5-HT4 agonist. No cardiovascular toxicity

Used for the treatment of chronic constipation in women.
Chloride Channel Activator

Chloride channels are critical to the digestive process because they promote fluid to release into the intestines.

**Lubiprostone**

PG analog

Stimulates type 2 chloride channel (ClC-2) in the small intestine and this increases liquid secretion in the intestine which stimulates intestinal motility & bowel movement within 24 hours of taking one dose.

Used in the treatment of chronic constipation.

Approved for the treatment of women with IBS with predominant constipation.

Its efficacy for men with IBS is unproven.

Should be avoided in women of child-bearing age.

Causes nausea (30%) due to delayed gastric emptying.
Antiemetic Agents

Nausea and vomiting may be manifestations of a wide variety of conditions, including:

- Adverse effects of medications.
- Systemic disorders or infections.
- Pregnancy.
- Vestibular dysfunction.
- CNS infection or increased pressure.
- Peritonitis.
- Hepatobiliary disorders.
- Radiation or chemotherapy.
- GIT obstruction, dysmotility, or infections.
Pathophysiology
The brainstem "vomiting center" coordinates vomiting through interactions with cranial nerves VIII and X and neural networks in the nucleus tractus solitarius that control respiratory, salivatory, and vasomotor centers.

Vomiting center contains high conc of:
M1 receptors.
H1 receptors.
Neurokinin 1 (NK1) receptors.
5-HT3 receptors.
D2 receptors, opioid receptors, 5-HT3 receptors & neurokinin NK1 receptors. (CTZ) or area postrema is outside BBB but is accessible to emetogenic stimuli in the blood or cerebrospinal fluid.

Irritation of GI by chemotherapy, radiation, distention, or gastroenteritis leads to release of 5-HT and activation of 5-HT3 receptors, which stimulate vagal afferent input to the VC and CTZ.
Serotonin 5-HT3 Antagonists

Ondansetron oral or IV
Granisetron half-life 4–9 h
Dolasetron
Palonosetron half-life 40 h

Block central 5-HT3 and peripheral (main effect) 5-HT3 receptors on extrinsic intestinal vagal and spinal afferent nerves.
They prevent emesis due to vagal stimulation and chemotherapy.
Other emetic stimuli such as motion sickness are poorly controlled.
Uses
Prevention of acute chemotherapy-induced nausea and emesis and postoperative nausea and vomiting.
Their efficacy is enhanced by combination therapy with dexamethasone and NK1-receptor antagonist.
Prevention and treatment of nausea and vomiting in patients undergoing radiation therapy.

Adverse effects:
Headache, dizziness, and constipation.
Cause a small prolongation of the QT interval.
Neurokinin 1 Receptor (NK1) Antagonists

Have antiemetic properties through central blockade in the area postrema.

Aprepitant

Used in combination with 5-HT3-receptor antagonists and corticosteroids for the prevention of acute and delayed nausea and vomiting from chemotherapy.

Adverse effects:
May cause fatigue, dizziness, and diarrhea.
Antipsychotic drugs

Prochlorperazine
Promethazine
Droperidol
Droperidol

Antiemetics due to inhibition of dopamine and muscarinic receptors.
Sedative effects due to antihistamine activity. **Droperidol** is extremely sedating.
Extrapyramidal effects and hypotension may occur.
**Droperidol** may prolong the QT interval, rarely.
Benzodiazepines

Lorazepam

Diazepam

Reduce anticipatory vomiting caused by anxiety.
H1 Antihistamines & Anticholinergic Drugs

Particularly useful in **motion sickness**.
May cause dizziness, sedation, confusion, dry mouth, cycloplegia, and urinary retention.

**Diphenhydramine, Dimenhydrinate**
Have significant anticholinergic properties.

**Meclizine**
Minimal anticholinergic properties and less sedating.
Used for the prevention of motion sickness and the treatment of **vertigo due to labyrinth dysfunction**.

**Hyoscine** (scopolamine)
Very high incidence of anticholinergic effects.
It is better tolerated as a transdermal patch.
Cannabinoids

Dronabinol, Nabilone
Delta-9- tetrahydrocannabinol from marijuana. Psychoactive agents.
Used as appetite stimulants and for chemotherapy-induced vomiting.
Mechanisms for these effects are not understood.

Adverse effects
Euphoria, dysphoria, sedation, hallucinations, dry mouth, and increased appetite.
May result in tachycardia, conjunctival injection (redness of the white sclera of the eye) and orthostatic hypotension.
Drugs Used to Treat Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), 2 distinct disorders: Ulcerative colitis & Crohn's disease. Etiology & pathogenesis are unknown.

Crohn's can affect any part of the GIT from mouth to anus, although a majority of the cases start in the terminal ileum. Ulcerative colitis, in contrast, is restricted to the colon and the rectum. Ulcerative colitis is restricted to the mucosa, while Crohn's disease affects the whole bowel wall. Crohn's disease and ulcerative colitis present with extra-intestinal manifestations (such as liver problems, arthritis, skin manifestations and eye problems) in different proportions.
Aminosalicylates

5-aminosalicylic acid (5-ASA)

Aminosalicylates work topically (not systemically) in areas of diseased gastrointestinal mucosa.

Up to 80% of unformulated 5-ASA is absorbed from the small intestine and does not reach the distal small bowel or colon in appreciable quantities.

A number of formulations deliver 5-ASA to various distal segments of the small bowel or the colon.
Azo Compounds

Sulfasalazine, Balsalazide, Olsalazine

5-ASA bound by an azo (N=N) bond to an inert compound or to another 5-ASA molecule

The azo structure markedly reduces absorption of the parent drug from the small intestine.

In the terminal ileum and colon, resident bacteria cleave the azo bond by means of an azoreductase enzyme, releasing 5-ASA.
Mesalazine Compounds

**Pentasa:**
Timed-release microgranules that release 5-ASA throughout the small intestine.

**Asacol:**
5-ASA coated in a pH-sensitive resin that dissolves at the pH of the distal ileum and proximal colon.

5-ASA also delivered as:

- Enema *(Rowasa)*
- Suppositories *(Canasa)*.
The mechanism of action of 5-ASA is not certain. Several mechanisms were proposed, including:

1- Inhibition of cytokine synthesis
2- Inhibition of prostaglandin and leukotriene synthesis
3- Free radical scavenging
4- Immunosuppressive activity
   5-ASA inhibits both T-cell proliferation and subsequent activation and differentiation.
5- Impairment of white cell adhesion and function.
Clinical Uses

5-ASA drugs are first-line agents for treatment of mild to moderate active ulcerative colitis.

Their efficacy in Crohn's disease is unproven, although used as first-line therapy for mild to moderate disease involving the colon or distal ileum.

Adverse Effects:
Due to systemic absorption: especially in slow acetylators:
Nausea, headache, arthralgia, myalgia, bone marrow suppression, and malaise.
Also allergic reactions, oligospermia, and folate deficiency.
Glucocorticoids
Inhibit production of inflammatory cytokines and chemokines; reduce expression of inflammatory cell adhesion molecules; and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2, and NF-κB.

Clinical Uses:
Moderate to severe active IBD.
Not useful for maintenance.

Prednisolone  Orally or IV.
Hydrocortisone  Rectally, preferred for rectal and sigmoid involvement.

Budesonide
A controlled-release oral formulation, releases the drug in the distal ileum and colon.
For ileal and proximal colon involvement.
Antimetabolites:
Azathioprim
6-Mercaaptopurine.

Are purine analogs; which produce thioguanine nucleotides (Active form).

Immunosuppressants.
Inhibit purine nucleotide metabolism and DNA synthesis and repair, resulting in inhibition of cell division and proliferation and may promote T-lymphocyte apoptosis.
Clinical Use:
Onset delayed for 17 weeks.
Used in induction and maintenance of remission.
Allow dose reduction or elimination of steroids.

Adverse Effects:
Nausea, vomiting, bone marrow suppression, hepatic toxicity and allergic reactions (fever, rash, pancreatitis, diarrhea and hepatitis).
Allopurinol increases levels of the drugs.
Methotrexate:
Antimetabolite, Used in cancer chemotherapy, rheumatoid arthritis and psoriasis.

Mechanism of action:
Inhibition of dihydrofolate reductase enzyme which is important in the synthesis of thymidine and purines.

- At high doses it inhibits cellular proliferation.
- At low doses used in IBD, it interferes with the inflammatory actions of interleukin-1, stimulates adenosine release, apoptosis and death of activated T lymphocytes.
Uses
Induction and maintenance of remissions of *Crohn’s Disease*.

Adverse effects:
At high doses, can cause:
bone marrow depression,
megaloblastic anemia,
aloepecia and
mucositis.
Renal insufficiency may increase risk of hepatic accumulation and toxicity.
Side effects counteracted by *folate* supplementation.
Anti-Tumor Necrosis Factor Therapy

TNF-α is one of the principal cytokines mediating the TH1 (helper T cell type 1) immune response characteristic of Crohn's disease.

Infliximab

A chimeric immunoglobulin (25% mouse, 75% human) that binds to and neutralizes TNF-α.

Infliximab binds to both soluble & transmembrane forms of TNF-α and inhibits their ability to bind to TNF receptors and may cause lysis of these cells.

Given by IV infusion.

Half life 8-10 days with persistence of antibodies in plasma for 8-12 weeks

Used in acute and chronic treatment of patients with moderate to severe Crohn's disease.

Also for refractory ulcerative colitis.
Response might be lost due to development of antibodies to infliximab.

Side Effects:
Acute:
  fever, chills, urticaria, or even anaphylaxis
Delayed:
  serum sickness–like reactions may develop after infliximab infusion, but lupus-like syndrome occurs only rarely.

Antibodies to infliximab can decrease its clinical efficacy.

Therapy is associated with increased incidence of respiratory infections; reactivation of TB. Infliximab also is contraindicated in patients with severe congestive heart failure.
Adalimumab
Fully humanized IgG antibody, given SC.

Certolizumab
Polyethylene glycol Fab fragment of humanized anti-TNF-α, also given SC.

Immunogenicity appears to be less of a problem than that associated with infliximab.
Natalizumab

Humanized IgG4 monoclonal antibody against the cell adhesion molecule α 4-integrin subunit. Prevents binding of several integrins on circulating inflammatory cells to vascular adhesion molecules.

Used for patients with moderate to severe Crohn's disease who have failed other therapies.

Given by IV infusion every 4 weeks, and patients should not be on other immune suppressants to prevent the risk of progressive multifocal leukoencephalopathy (rare and usually fatal viral disease).

Adverse effects include acute infusion reactions & a small risk of opportunistic infections.
Pancreatic Enzyme Supplements
Contain a mixture of amylase, lipase, and proteases.
Used to treat pancreatic enzyme insufficiency.

**Pancrelipase.**
Available in both non-enteric-coated (given with acid suppression therapy) and enteric-coated preparations.
Administered with each meal and snack.
Excessive doses may cause diarrhea and abdominal pain.
The high purine content of pancreas extracts may lead to hyperuricosuria and renal stones.